Last updated on July 2019

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection


Brief description of study

The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3 years of age with respiratory syncytial virus (RSV) disease (hospitalized participants [Cohort 1] or outpatients [Cohort 2]).

Detailed Study Description

JNJ-53718678 is an investigational respiratory syncytial virus (RSV) specific fusion inhibitor and is under development for the treatment of RSV infection, which results in an upper and/or lower respiratory tract illness. The primary hypothesis of this study is that JNJ-53718678 has antiviral activity against RSV (that is, results in a decrease in RSV nasal viral load from immediately prior to first dose of study drug until Day 5). This will be assessed by a positive dose-response relationship of JNJ-53718678 compared to placebo. Besides the RSV nasal viral load through day 5, other timepoints will also be evaluated as well as other nasal viral load related parameters. In addition, the evolution of signs and symptoms of RSV disease will be evaluated. Participants' safety will be monitored throughout the study by evaluating the occurrence and severity of adverse events and by laboratory and electrocardiogram measurements. Study participants will be identified when they are hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital (Cohort 1) or present for medical care as outpatients (Cohort 2) with symptoms of an acute respiratory illness supporting a diagnosis of RSV infection. Eligible participants will be randomized 1:1:1 to receive either a low or a high dose of JNJ 53718678 or placebo and will be receiving study treatment for 7 days. They will be followed up for 3 weeks after the last dose. The total study duration for each participant will be approximately 29 days.

Clinical Study Identifier: NCT03656510

Find a site near you

Start Over

FOMAT Medical Research

Ventura, CA United States
  Connect »

Elite Clinical Trials

Blackfoot, ID United States
  Connect »

Saltzer Medical Group

Nampa, ID United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Craig A. Spiegel, MD

Bridgeton, MO United States
  Connect »

Santiago Reyes, MD

Oklahoma City, OK United States
  Connect »

Coastal Pediatric Research

Summerville, SC United States
  Connect »

Sanford Health

Sioux Falls, SD United States
  Connect »

Gadolin Research

Beaumont, TX United States
  Connect »

Seattle Children's Hospital

Seattle, WA United States
  Connect »

West Virgina University

Charleston, WV United States
  Connect »

West Virginia University

Morgantown, WV United States
  Connect »

Hospital Pedro de Elizalde

City of Buenos Aires, Argentina
  Connect »

Fundaci n Respirar

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

Hospital Italiano de La Plata

Ciudad De La Plata, Argentina
  Connect »

Clinica Mayo de UMCB

San Miguel de Tucuman, Argentina
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

ULB H pital Erasme

Anderlecht, Belgium
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

Hospital Tuanku Fauziah

Pusat Bandar Kangar, Malaysia
  Connect »

OOO "MDP-Medical Group"

Odintsovo, Russian Federation
  Connect »

Rostov State Medical University

Rostov on Don, Russian Federation
  Connect »

OOO 'Medical Technologies'

St. Petersburg, Russian Federation
  Connect »

OOO 'Arsvite North-West'

St. Petersburg, Russian Federation
  Connect »

LLC Kurator

St. Petersburg, Russian Federation
  Connect »

Tygrberg Hospital

Bellville, South Africa
  Connect »

Josha Research

Bloemfontein, South Africa
  Connect »

Paarl Hospital

Cape Town, South Africa
  Connect »

VX Pharma

Pretoria, South Africa
  Connect »

Two Military Hospital

Wynberg, South Africa
  Connect »

Hosp. Del Mar

Barcelona, Spain
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, Spain
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

Eulji General Hospital

Seoul, Korea, Republic of
  Connect »

Kangbuk Samsung Hospital

Seoul, Korea, Republic of
  Connect »

Hospital Selayang

Batu Caves, Malaysia
  Connect »

RM Pharma Specialists

Benito Juarez, Mexico
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Jacobi Medical Center

Bronx, NY United States
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Hospital del Ni o Jes s

San Miguel de Tucumán, Argentina
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, Spain
  Connect »

Hospital Pedro de Elizalde

City Of Buenos Aires, Argentina
  Connect »

Rostov State Medical University

Rostov On Don, Russian Federation
  Connect »

Hosp. Clinico Univ. de Santiago

Santiago De Compostela, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.